{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:30Z","timestamp":1790960790007,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Plasma samples taken at different time points from donors who received either AstraZeneca (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19) vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50% neutralizing antibody titres (NT\n                    <jats:sub>50<\/jats:sub>\n                    ) against Delta and VIC31 at 6 months compared to 2 weeks after the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender were not found to significantly impact our results. These findings indicate that vaccine matching may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient neutralising antibodies against emerging variants of concern, especially Omicron, amidst the challenges of ensuring vaccine equity worldwide.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.883612","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T03:42:26Z","timestamp":1652758946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant"],"prefix":"10.3389","volume":"13","author":[{"given":"Nagendrakumar B.","family":"Singanallur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrus Jansen","family":"van Vuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kuiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Gwini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Goldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor W.","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim R.","family":"Blasdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Tachedjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Mangalaganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Caly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Druce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Juno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seshadri S.","family":"Vasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"B1","volume-title":"Coronavirus Pandemic (COVID-19)","author":"Ritchie","year":"2020"},{"key":"B2","unstructured":"World Bank Country and Lending Groups2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/v14040800","article-title":"Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies Against Delta and Omicron in Mice","volume":"14","author":"Jansen van Vuren","year":"2022","journal-title":"Viruses"},{"key":"B4","unstructured":"What Recent Evidence do We Have That Omicron is Evading Immunity and What are the Implications?2022"},{"key":"B5","unstructured":"What Evidence do We Have That Omicron is Evading Immunity and What are the Implications?2021"},{"key":"B6","unstructured":"Tracking SARS-CoV-2 Variants2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41541-020-00246-8","article-title":"Experimental and in Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614G Mutation in SARS-CoV-2 Spike Protein","volume":"5","author":"McAuley","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.1c00276","article-title":"Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative","volume":"7","author":"Malladi","year":"2021","journal-title":"ACS Infect Dis"},{"key":"B9","unstructured":"Vaxzevria (AstraZeneca)2022"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/BF01863914","article-title":"Beitrag Zur Kollektiven Behandlung Pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn-Schmiedebergs Archiv F\u00fcr Experiment Pathologie Und Pharmakolog"},{"key":"B11","volume-title":"Personal Communication (16 February 2022) to S.S. Vasan","author":"Sitaras","year":""},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly Accurate Protein Structure Prediction With AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ilab031","article-title":"\u201cBut Mouse, You Are Not Alone\u201d: On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting Mice","volume":"12","author":"Kuiper","year":"2022","journal-title":"ILAR J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"044130","DOI":"10.1063\/5.0014475","article-title":"Scalable Molecular Dynamics on Cpu and Gpu Architectures With Namd","volume":"153","author":"Phillips","year":"2020","journal-title":"J\u00a0Chem Phys"},{"key":"B15","article-title":"R: A Language and Environment for Statistical Computing","volume-title":"R Foundation for Statistical Computing","year":"2019"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1010161","DOI":"10.1371\/journal.ppat.1010161","article-title":"Advances and Gaps in SARS-CoV-2 Infection Models","volume":"18","author":"C\u00e9sar Mu\u00f1oz-Fontela","year":"2022","journal-title":"PloS Pathog"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"New Engl J Med"},{"key":"B18","unstructured":"COVID-19 Leading Cause of Death Ranking2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","article-title":"Plasma Neutralization of the SARS-CoV-2 Omicron Variant","volume":"386","author":"Schmidt","year":"2021","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 Omicron Variant Neutralization in Serum From Vaccinated and Convalescent Persons","volume":"386","author":"R\u00f6ssler","year":"2022","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c01243","article-title":"R346k Mutation in the Mu Variant of SARS-CoV-2 Alters the Interactions With Monoclonal Antibodies From Class 2: A Free Energy Perturbation Study","volume":"62","author":"Fratev","year":"2022","journal-title":"J Chem Inf Model"},{"key":"B22","unstructured":"COVID Data Tracker2022"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS-CoV-2 Omicron Variant Replication in Human Bronchus and Lung Ex Vivo","volume":"603","author":"Hui","year":"2022","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00232-006-0861-0","article-title":"Mechanisms of Acid and Base Secretion by the Airway Epithelium","volume":"211","author":"Fischer","year":"2006","journal-title":"J Membr Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2148-4-21","article-title":"Moderate Mutation Rate in the SARS Coronavirus Genome and Its Implications","volume":"4","author":"Zhao","year":"2004","journal-title":"BMC Evol Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (Covid-19) by the Numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"eLife"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00694-10","article-title":"Viral Mutation Rates","volume":"84","author":"Sanju\u00e1n","year":"2010","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/tbed.13588","article-title":"Supporting Pandemic Response Using Genomics and Bioinformatics: A Case Study on the Emergent SARS-CoV-2 Outbreak","volume":"67","author":"Bauer","year":"2020","journal-title":"Transbound Emerg Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2471\/BLT.20.253591","article-title":"Variant Analysis of SARS-CoV-2 Genomes","volume":"98","author":"Koyama","year":"2020","journal-title":"Bull World Health Organ"},{"key":"B31","unstructured":"ATAGI Statement on Defining 'Up-to-Date' Status for COVID-19 Vaccination2022"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S2213-2600(22)00010-8","article-title":"Fourth Dose of Covid-19 Vaccines in Israel","volume":"10","author":"Burki","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.15.22270948","article-title":"4th Dose Covid mRNA Vaccines\u2019 Immunogenicity & Efficacy Against Omicron VOC","author":"Regev-Yochay","year":"2022","journal-title":"medRxiv"},{"key":"B34","volume-title":"Personal Communication (22 February 2022) to S.S","author":"Mandelboim","year":""},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21267877","article-title":"Immunosequencing and Epitope Mapping Reveal Substantial Preservation of the T Cell Immune Response to Omicron Generated by SARS-CoV-2 Vaccines","author":"May","year":"2021","journal-title":"medRxiv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.26.21268380","article-title":"SARS-CoV-2 Spike T Cell Responses Induced Upon Vaccination or Infection Remain Robust Against Omicron","author":"Keeton","year":"2021","journal-title":"medRxiv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and Heterologous COVID-19 Booster Vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"New Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous Prime-Boost: Breaking the Protective Immune Response Bottleneck of COVID-19 Vaccine Candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B39","unstructured":"JayaramanKS\n          Ferret Chosen as Animal Model to Test Coronavirus Vaccines. Nature India (5 April 2020)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41541-021-00315-6","article-title":"ChAdOx1 Ncov-19 (AZD1222) Vaccine Candidate Significantly Reduces SARS-CoV-2 Shedding in Ferrets","volume":"6","author":"Marsh","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 Ncov-19\/AZD1222 Vaccination Reduces Viral Shedding After SARS-CoV-2 D614G Challenge in Preclinical Models","volume":"13","author":"Van Doremalen","year":"2021","journal-title":"Sci Trans Med"},{"key":"B42","unstructured":"Landmark Coronavirus Study to Trial Inhaled Imperial and Oxford Vaccines2020"},{"key":"B43","unstructured":"AstraZeneca Vaccine: Did Nationalism Spoil UK's 'Gift to the World'?2022"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.883612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T03:42:34Z","timestamp":1652758954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.883612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2022.883612"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.883612","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.20.22271237","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"article-number":"883612"}}